The biology of T cell defects in systemic lupus erythematosus (SLE), examining cellular, biochemical, molecular, and metabolic abnormalities and their relevance to disease pathogenesis, biomarkers, personalized medicine, and therapeutic development.
Multiple T cell defects in SLE contribute to disease pathogenesis and organ damage, and understanding these abnormalities at various biological levels opens avenues for biomarker development, personalized medicine, and targeted therapeutics.
As a review/perspective article, it does not present original clinical trial data or patient outcomes; conclusions depend on the quality and scope of the studies reviewed.
Clinicians should be aware that T cell biology in SLE is multifaceted, with defects at cellular, molecular, and metabolic levels that may inform future biomarker use and personalized treatment strategies.
Explore related topics